申请人:Li Xiaolin
公开号:US20100190811A1
公开(公告)日:2010-07-29
The invention provides a novel class of pyrimidine derivatives, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of c-kit, PDGFRα and PDGFRβ kinases.
本发明提供了一种新的嘧啶衍生物类,包括这些化合物的药物组合物以及使用这些化合物治疗或预防与异常或非正常激酶活性相关的疾病或疾病的方法,特别是涉及c-kit、PDGFRα和PDGFRβ激酶异常激活的疾病或疾病。